Price$125.57+32.50 (+34.92%)
2026-03-042026-06-05
News · 26 weeks133+57%
2025-12-142026-06-07
Mix7590d
- Insider48(64%)
- Other15(20%)
- SEC Filings7(9%)
- Analyst3(4%)
- Earnings2(3%)
Latest news
25 items- INSIDERDirector Krognes Steve E. sold $1,231,522 worth of shares (9,294 units at $132.51), decreasing direct ownership by 48% to 10,222 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- ANALYSTGoldman initiated coverage on Guardant Health with a new price targetGoldman initiated coverage of Guardant Health with a rating of Buy and set a new price target of $165.00
- INSIDERDirector Joyce Meghan V. exercised 10,000 shares at a strike of $38.05 and sold $1,269,809 worth of shares (10,000 units at $126.98) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- ANALYSTWolfe Research resumed coverage on Guardant Health with a new price targetWolfe Research resumed coverage of Guardant Health with a rating of Outperform and set a new price target of $150.00
- ANALYSTGuardant Health upgraded by Evercore ISI with a new price targetEvercore ISI upgraded Guardant Health from In-line to Outperform and set a new price target of $160.00
- INSIDERDirector Krognes Steve E. converted options into 154 shares, increasing direct ownership by 0.80% to 19,516 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel sold $130,060 worth of shares (1,000 units at $130.06), decreasing direct ownership by 61% to 639 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Legal Officer Saia John G. sold $1,250,836 worth of shares (10,000 units at $125.08), decreasing direct ownership by 22% to 35,950 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual MeetingNew performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer companion diagnostic Findings show how Guardant360 Liquid CDx can expand access to targeted therapies by identifying actionable biomarkers missed by genomic testing Presentations reinforce Guardant's role advancing genomic and epigenomic profiling, characterizing tissue-free MRD and recurrence monitoring, and expanding biomarker-guided precision oncology Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing ad
- PRAmerican Cancer Society Recommends Guardant Health's Shield Blood Test in Updated Colorectal Cancer Screening GuidelinesUpdated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are not up to date with their colorectal cancer screening Shield is the first and only FDA-approved blood test included in both ACS and NCCN guidelines Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not completed stool-based or visual examination screening tests. In an effort to address persistent
- INSIDERChief Commercial Officer Freeman Chris exercised 24,406 shares at a strike of $32.86 and sold $2,896,360 worth of shares (24,406 units at $118.67) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERChief Legal Officer Saia John G. sold $2,130,229 worth of shares (20,000 units at $106.51), decreasing direct ownership by 30% to 45,950 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Talasaz Amirali sold $23,076,690 worth of shares (210,000 units at $109.89) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Clark Ian T sold $735,049 worth of shares (6,876 units at $106.90) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel exercised 1,000 shares at a strike of $32.55 and sold $133,864 worth of shares (1,250 units at $107.09), decreasing direct ownership by 13% to 1,639 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- PRFDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded FootprintGuardant Health's new FDA-approved liquid biopsy integrates genomic and epigenomic insights to provide a more complete, actionable view of cancer from a simple blood draw Approval strengthens Guardant's leadership in comprehensive molecular profiling and advances a unified testing experience across liquid and tissue Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advance
- INSIDERDirector Tariq Musa converted options into 250 shares and sold $11,131 worth of shares (116 units at $95.96), increasing direct ownership by 2% to 8,662 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 14% to 1,889 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Technology Officer Chudova Darya converted options into 8,705 shares and covered exercise/tax liability with 4,679 shares, increasing direct ownership by 6% to 74,402 units (SEC Form 4) to satisfy withholding tax4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who we
- SECSEC Form SCHEDULE 13G filed by Guardant Health Inc.SCHEDULE 13G - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERCo-Chief Executive Officer Talasaz Amirali sold $5,016,000 worth of shares (50,000 units at $100.32) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 10-Q filed by Guardant Health Inc.10-Q - Guardant Health, Inc. (0001576280) (Filer)
GH FAQ
7 questionsWhat does Guardant Health Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic...Where does GH stock trade?
Guardant Health Inc. (GH) is listed on NASDAQ.What sector and industry is GH in?
Guardant Health Inc. operates in the Health Care sector, Medical Specialities industry.When did Guardant Health Inc. go public?
Guardant Health Inc. (GH) completed its IPO in 2018.What are analysts saying about GH?
Guardant Health Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-06-05.What companies are similar to GH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare GH side-by-side with any of them on Quantisnow.How can I track GH on Quantisnow?
Quantisnow aggregates Guardant Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GH to receive live email and push alerts on every new disclosure.